Eszopiclone Cost Effective in Long-Term Treatment of Insomnia
May 17, 2005 - 7:25:38 PM

Sepracor Inc. (Nasdaq: SEPR - News) announces the presentation of results from two analyses designed to assess potential pharmacoeconomic benefits associated with the use of LUNESTA(TM) brand eszopiclone in the long-term treatment of insomnia.

LUNESTA is the first and only sleep aid approved by the U.S. Food and Drug Administration (FDA) for long-term use. These data were presented yesterday at the 10th Annual International Society for Pharmacoeconomics and Outcomes Research Meeting (ISPOR) held in Washington, DC.

Forecasting the Impact of Adding a New Drug on Formulary Using Medical Claims Data and Clinical Literature: A Case Study of Insomnia Treatment

Using medical claims and clinical trial data, a budget impact model was developed to help health plans estimate the cost of adding new drugs to their formularies. The utility of the model was illustrated by considering LUNESTA.

Analyses of medical claims and clinical trial data for over 85,000 patients who used several insomnia medications showed that patient costs depend upon drug efficacy. Therefore, total costs for LUNESTA were illustrated by focusing on the drug's efficacy. Total sleep time was the primary efficacy measure considered by this illustration, but it included five other sleep efficacy endpoints that could also be considered by this model, including patient-reported time to sleep onset and number of nighttime awakenings, objective measures of time to sleep onset, sleep efficiency and wake time after sleep onset (WASO; a sleep maintenance measurement of the amount of time spent awake after initially falling asleep).

When using the primary efficacy measure of total sleep time, the model showed that, for a health plan with 100,000 members, introduction of LUNESTA to the health plan's formulary for the treatment of insomnia would decrease total annual expenditures for insomnia patients by approximately $587,881. Health plans may tailor the results of this model to reflect their unique populations by changing the model's assumptions about the proportion of patients between the ages of 18 and 64, the proportion of patients having insomnia and the proportion of patients using other medications. Due to this flexibility, different assumptions could yield different results.

"Results may vary for different plans, but this study demonstrated that using LUNESTA for the treatment of insomnia may reduce health care costs," said Ronald J. Ozminkowski, Ph.D., Director of Health and Productivity Research at Thomson Medstat of Ann Arbor, MI and principal researcher of this study.

Cost Effectiveness of Longer-Term Treatment With Eszopiclone 3 mg in Adults With Primary Insomnia

The second presentation at ISPOR was a decision analytical model that was developed based on the six-month, placebo-controlled trial that assessed the effect of LUNESTA 3 mg versus placebo on various sleep and daytime-function parameters.(1)

The findings from this six-month study were combined with quality of life and cost data from published literature and claims databases. For the purposes of this analysis, patients were classified over time as either "recovered" or "non-recovered" from insomnia based upon a composite index of eight sleep and daytime-function measures recorded during the six- month study.

This model is based on certain assumptions, including the reasonable assumption that the beneficial cost impact of restoring normal sleep is immediate; other assumptions may yield different results.

The results of this model demonstrated that the cost effectiveness associated with use of LUNESTA was comparable to, or better than, the cost effectiveness of broadly accepted treatments for other conditions, such as benign prostatic hyperplasia (BPH), menopausal symptoms, migraine, overactive bladder, irritable bowel syndrome and adult herpes infections.

"For years, sleep medicine experts have argued that chronic primary insomnia is a costly condition and that treating it with pharmacotherapy could be cost effective. This analysis provides, for the first time, some preliminary evidence that this may be true. Long-term treatment with LUNESTA may not only help reduce the symptoms of insomnia but has the potential to do it cost effectively by reducing its direct and indirect economic burden and improving the health-related quality of life of insomnia patients," said Marc Botteman, MSc, Managing Partner, Pharmerit North America and formerly Executive Director of Abt Associates, Inc., both of Bethesda, MD, and lead author of this study.


LUNESTA 1 mg, 2 mg and 3 mg tablets are available by prescription in pharmacies nationwide. LUNESTA is indicated for the treatment of insomnia in patients who experience difficulty falling asleep as well as for the treatment of patients who are unable to sleep through the night (sleep maintenance difficulty).

Data from a landmark, long-term (six-month), double-blind, placebo- controlled safety and efficacy study in 788 patients served as a basis for the FDA's decision to approve LUNESTA for long-term use. Sepracor's six-month study of LUNESTA was the first of its kind for a prescription non- benzodiazepine for the treatment of insomnia.

An estimated 100 million adult Americans suffer from either chronic or occasional insomnia.(2) Symptoms of insomnia include difficulty falling asleep, awakening frequently during the night, waking up too early, an inability to fall back to sleep or awakening feeling unrefreshed.

Important Safety Information

LUNESTA works quickly and should only be taken immediately before bedtime. Be sure you have at least eight hours to devote to sleep before becoming active. You should not engage in any activity after taking LUNESTA that requires complete alertness, such as driving a car or operating machinery. You should use extreme care when engaging in these activities the morning after taking LUNESTA. Do not use alcohol while taking any sleep medicine. All sleep medicines carry some risk of dependency. Do not use sleep medicines for extended periods without first talking to your doctor. Side effects may include unpleasant taste, headache, drowsiness and dizziness.

All rights reserved by RxPG Medical Solutions Private Limited ( )